Smoking outcome by psychiatric history after behavioral and varenicline treatment.
Treatment outcomes were compared across smokers enrolled in the COMPASS cessation trial with (positive psychiatric history [PH+], n = 271) and without (PH-, n = 271) a diagnosis of PH based on medical record evidence of anxiety, depression, psychotic disorder, or bipolar disorder. Everyone received behavioral counseling plus varenicline and was followed for 6 months post quit date. PH+ smokers took varenicline for fewer days on average (59.4 vs. 68.5, p < or = .01) but did not differ in their use of behavioral treatment. PH+ smokers were more likely to report anxiety and depression, but side-effect intensity ratings did not differ after adjusting for multiple comparisons. Overall, all side effects were rated as moderate intensity or less. Groups had similar 30-day abstinence rates at 6 months (31.5% PH+ vs. 35.4% PH-, p = .35). In sum, having a psychiatric diagnosis in this trial did not predict worse treatment outcome or worse treatment side effects.
McClure
Jennifer B
JB
Group Health Research Institute, Seattle, WA 98101, USA. mcclure.j@ghc.org
Swan
Gary E
GE
Catz
Sheryl L
SL
Jack
Lisa
L
Javitz
Harold
H
McAfee
Tim
T
Deprey
Mona
M
Richards
Julie
J
Zbikowski
Susan M
SM
D000328:Adult; D001521:Behavior Therapy / Q000379:methods*; D001552:Benzazepines / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D037001:Directive Counseling / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000150:complications* / Q000503:physiopathology; D008875:Middle Aged; D018722:Nicotinic Agonists / Q000009:adverse effects / Q000627:therapeutic use; D011810:Quinoxalines / Q000009:adverse effects / Q000627:therapeutic use*; D016540:Smoking Cessation / Q000379:methods*; D016896:Treatment Outcome; D000068580:Varenicline
D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D000068580:Varenicline